Advanced Proteome Therapeutics Company

Cancer is a complex disease, and for therapies to be maximally effective, they must distinguish between normal and cancerous cells. Combination therapies have been employed to counter the multiple mechanisms that tumors use to evade the immune response and resist the efficacious effects of therapeutics. Despite continuing challenges, useful synergies have been obtained with a combination of individual drugs, and, as a result, a broad range of drug types are now being combined because of the promise and the compelling rationale behind combination therapy. Thus, effective treatment for cancer requires not only the discovery of individual drugs with antitumor activity, but also knowledge of the best way to combine these drugs.

Estimated Revenue: Less than $1M
Funding Status: IPO
Employee Number: 11-50
Industry: BioTech
Last Funding Type: Post-IPO Equity
Headquarters: Boston, Massachusetts, United States
Founded Date: 2007-01-01
Total Funding: 3795356
Technology: Others